Publication Name	World Journal of Clinical Cases
Manuscript ID	119171
Country	Pakistan

Category	Dermatology
Manuscript Type	Systematic Reviews
Article Title	Comparing lebrikizumab with other systemic immunomodulators for moderate to severe atopic dermatitis: An updated systematic review
Manuscript Source	Invited Manuscript
All Author List	Chris Alphonse, Muhammad Irfan, Sergio Camilo Torres Céspedes, Chisom Nwanejuafor, Kashfia Nayeem, Elias Hertan, Vrinda Mohan, Haripriya Gupta, Noor Ul Ain Fatima, Luis Adrian Guadarrama Mendoza, Azkah Sardar, Alexander Michael Diaz and Inshal Jawed
Funding Agency and Grant Number
Corresponding Author	Inshal Jawed, Department of Medicine, Dow University of Health Sciences, Baba-e-urdu Karachi, Karachi 75350, Sindh, Pakistan. inshaljwd@gmail.com
Key Words	Atopic dermatitis; Lebrikizumab; Dupilumab; Tralokinumab; Janus kinase inhibitors; Systematic review; Network meta-analysis; GRADE assessment
Core Tip	An updated systematic review of 28 studies (10847 patients) shows that the efficacy of lebrikizumab, a high-affinity anti-interleukin-13 monoclonal antibody, is equivalent to that of dupilumab and superior to that of tralokinumab in moderate-to-severe atopic dermatitis (AD). The results showed that lebrikizumab performs better than baricitinib and has efficacy comparable to that of most Janus kinase inhibitors. It also has a better safety profile, with no boxed warnings. Data from real-world and extension studies confirm sustained efficacy. Evidence of moderate to high quality suggests lebrikizumab is a reasonable first-line biologic for moderate to severe AD requiring systemic therapy.
Citation	Alphonse C, Irfan M, Torres Céspedes SC, Nwanejuafor C, Nayeem K, Hertan E, Mohan V, Gupta H, Fatima NUA, Guadarrama Mendoza LA, Sardar A, Diaz AM, Jawed I. Comparing lebrikizumab with other systemic immunomodulators for moderate to severe atopic dermatitis: An updated systematic review. World J Clin Cases 2026; In press

Received	2026-01-21 00:57
Peer-Review Started	2026-01-21 01:44
First Decision by Editorial Office Director	2026-02-13 07:28
Return for Revision	2026-02-13 07:28
Revised	2026-02-26 02:02
Publication Fee Transferred
Second Decision by Editor	2026-03-18 02:37
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-03-18 04:15
Articles in Press	2026-03-18 04:15
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com